FBT:NYE-First Trust NYSE Arca Biotechnology Index Fund (USD)

ETF | Health |

Last Closing

USD 178.24

Change

+5.25 (+3.03)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-21 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+2.32 (+1.66%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

+1.16 (+1.74%)

USD 2.66B
FXH First Trust Health Care AlphaD..

+1.54 (+1.42%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

+1.95 (+2.11%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.57 (+2.60%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.88 (+2.83%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+2.59 (+2.69%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+1.15 (+3.91%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+1.37 (+2.27%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.63 (+2.91%)

USD 8.55M

ETFs Containing FBT

FHM:CA 99.89 % 0.78 %

N/A

N/A
FBT:CA First Trust NYSE Arca Bio.. 0.00 % 0.00 %

+0.05 (+0.16%)

CAD 1.83M

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.24% 90% A- 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.24% 90% A- 85% B
Trailing 12 Months  
Capital Gain 16.53% 100% F 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.53% 100% F 62% D
Trailing 5 Years  
Capital Gain 20.05% 38% F 60% D-
Dividend Return 1.49% 42% F 4% F
Total Return 21.54% 38% F 48% F
Average Annual (5 Year Horizon)  
Capital Gain 1.25% 33% F 38% F
Dividend Return 1.58% 38% F 29% F
Total Return 0.33% 42% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 12.20% 86% B+ 74% C
Risk Adjusted Return 12.95% 38% F 29% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.